van Raalte, Daniƫl H.
Bjornstad, Petter
Cherney, David Z. I. http://orcid.org/0000-0003-4164-0429
de Boer, Ian H.
Fioretto, Paola http://orcid.org/0000-0003-3445-0387
Gordin, Daniel
Persson, Frederik http://orcid.org/0000-0001-6242-6638
Rosas, Sylvia E. http://orcid.org/0000-0002-9903-4002
Rossing, Peter http://orcid.org/0000-0002-1531-4294
Schaub, Jennifer A. http://orcid.org/0000-0001-8788-239X
Tuttle, Katherine http://orcid.org/0000-0002-2235-0103
Waikar, Sushrut S. http://orcid.org/0000-0003-4004-326X
Heerspink, Hiddo J. L. http://orcid.org/0000-0002-3126-3730
Article History
Accepted: 29 February 2024
First Online: 3 April 2024
Competing interests
: D.H.V.R. has consulting relationships with Bayer, Boehringer Ingelheim, Eli Lilly, Merck and Sanofi, and receives research operating funding from AstraZeneca, Boehringer Ingelheim-Eli Lilly Diabetes Alliance and MSD. Honoraria are transferred to employer Amsterdam UMC. P.B. reports serving or having served as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk and Horizon Pharma. P.B. also serves or has served on the advisory boards and/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. P.B. receives grant support from Eli Lilly, Novo Nordisk, AstraZeneca, Merck, and Horizon Pharma. D.Z.I.C. reports serving or having served as a consultant for Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk. He has received operational funding from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk. I.H.D.B. has received consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Cyclerion Therapeutics, George Clinical, Gilead, Goldfinch Bio, Ironwood, Medscape and Otsuka. P.F. has received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly company and Novo Nordisk. D.G. has received lecture or Advisory Board Honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Delta Medical Communications, EASD eLearning, Finnish Association for Vascular Surgery, Finnish Nephrology Association, Kidney and Liver Foundation in Finland. F.P. has served as a consultant, on advisory boards or as educator for AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Sanofi, Mundipharma, MSD, Novartis and Amgen, and has received research grants to institution from Novo Nordisk, Boehringer Ingelheim, Amgen and AstraZeneca. S.E.R. has participated as a member of scientific advisory boards for AstraZeneca, Bayer, and Travere. P.R. has received research support and personal fees from AstraZeneca, Bayer, and Novo Nordisk and personal fees from Abbott, Astellas, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead and Sanofi. All fees are given to Steno Diabetes Center Copenhagen. K.T. reports consulting relationships with Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer and Novo Nordisk, and receives research grants from Travere paid to employer, Providence Inland Northwest Health. S.S.W. is consultant for Wolters Kluwer, Bain, BioMarin, Goldfinch, GSK, Ikena, Strataca, Google, CANbridge, NovoNordisk, PepGen, Sironax and NovoNordisk, and expert witness for Davita, Pfizer, Dechert and Aurinia Pharmaceuticals. S.S.W. receives research funding from Vertex, Pfizer, JNJ and Natera. H.J.L.H. is consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novo Nordisk, ProKidney, Travere Therapeutics and Vifor Fresenius. He has received research support from AstraZeneca, Boehringer Ingelheim, Janssen and Novo Nordisk.